Stem cell investigation最新文献

{"title":"Survival analysis of multiple myeloma patients after autologous stem cell transplantation.","authors":"Ju Li,&nbsp;Yan Zhu","doi":"10.21037/sci.2019.10.05","DOIUrl":"https://doi.org/10.21037/sci.2019.10.05","url":null,"abstract":"Background\u0000Hematopoietic stem cell transplantation has been applied to treat the hematologic malignancies since the 1980s. However, allogenic transplantation has inherent complications such as graft-versus-host disease and graft failure. Autologous transplantation has become more and more popular because of its lower transplant-related mortality. This study was performed to analyze the possible prognostic factors for myeloma patients post stem cell transplantation.\u0000\u0000\u0000Methods\u0000Patients' information was collected by history review and follow-up through the phone call. Kaplan-Meier was used to exhibit overall survival (OS) and progression-free survival (PFS). Univariate and multivariate analyses were performed using Cox proportional hazards model. A P<0.05 is considered statistically significant.\u0000\u0000\u0000Results\u0000Thirty patients with multiple myeloma were included in this study, 7 of them died because of myeloma relapse and myeloma-associated complications. The average survival time was 29.8 months and the median follow-up was 25.1 months. The 1-year OS and PFS were 93.3% and 90.0%, respectively. Both the 3-year OS and PFS were 76.7%. In a variety of factors, improved renal function showed a good effect on the outcome of transplantation.\u0000\u0000\u0000Conclusions\u0000To prevent cancer relapse after autologous transplantation, it is of great significance to achieve a complete remission prior to the transplantation.","PeriodicalId":21938,"journal":{"name":"Stem cell investigation","volume":" ","pages":"42"},"PeriodicalIF":0.0,"publicationDate":"2019-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/sci.2019.10.05","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37626895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combination of the stromal vascular fraction and platelet-rich plasma accelerates the wound healing process: pre-clinical study in a Sprague-Dawley rat model.","authors":"Karina, Muhammad F. Samudra, I. Rosadi, I. Afini, Tias Widyastuti, S. Sobariah, Melinda Remelia, R. L. Puspitasari, I. Rosliana, Tri I Tunggadewi","doi":"10.21037/SCI.2019.06.08","DOIUrl":"https://doi.org/10.21037/SCI.2019.06.08","url":null,"abstract":"Background\u0000Adipose-derived stem cells (ADSCs) improve wound healing owing to their angiogenic potency. However, the production of large quantities of ADSCs for clinical applications is laborious. In this study, the efficacy of the stromal vascular fraction (SVF; non-expanded ADSCs) combined with platelet-rich plasma (PRP) which contains abundant growth factors, for wound healing was evaluated using an animal model.\u0000\u0000\u0000Methods\u0000PRP from venous blood and SVF from lipoaspirates were harvested from six donors. PRP, SVF, SVF + PRP, and saline solution as a negative control were injected to second degree burn wounds in the backs of 24 male Sprague-Dawley rats. On the seventh day after injection, rats were euthanized and wounds were analyzed microscopically and macroscopically.\u0000\u0000\u0000Results\u0000Wounds closed faster in the SVF + PRP group than in the control group or PRP or SVF alone groups, with less inflammation, prominent signs of re-epithelization, more skin appendages and blood vessels, and a higher rate of hair growth. No infection or rat death occurred during the trial.\u0000\u0000\u0000Conclusions\u0000The combination of SVF and PRP may provide an additive stimulatory effect to support angiogenesis and accelerate the wound healing process; accordingly, this combination is a potential alternative to ADSC treatment.","PeriodicalId":21938,"journal":{"name":"Stem cell investigation","volume":"6 1","pages":"18"},"PeriodicalIF":0.0,"publicationDate":"2019-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/SCI.2019.06.08","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45479706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stem Cell Ophthalmology Treatment Study (SCOTS): bone marrow derived stem cells in the treatment of Dominant Optic Atrophy.","authors":"Jeffrey N Weiss,&nbsp;Steven Levy","doi":"10.21037/sci.2019.11.01","DOIUrl":"https://doi.org/10.21037/sci.2019.11.01","url":null,"abstract":"<p><strong>Background: </strong>We report the results of 6 patients with Dominant Optic Atrophy (DOA) who met inclusion criteria and were treated in the Stem Cell Ophthalmology Treatment Study (SCOTS). SCOTS/SCOTS 2 is an Institutional Review Board approved and NIH registered (NCT03011541) clinical study that uses autologous bone marrow derived stem cells (BMSC) in the treatment of optic nerve and retinal disease.</p><p><strong>Methods: </strong>This is an open label, non-randomized clinical study using natural history of the disease as the comparator. BMSC were separated from aspirated autologous bone marrow with minimal manipulation using an FDA cleared Class II medical device. Patients were treated with combinations of retrobulbar, subtenons, intravitreal or subretinal placement of BMSC followed by intravenous injection of BMSC depending on the arm of the study chosen. There were no surgical complications.</p><p><strong>Results: </strong>Of the patients treated, 83.3% (5 of 6 patients) experienced visual improvements and in all of these cases both eyes improved. Ten eyes or 83.3% experienced gains in visual acuity with a median improvement of 2.125 Snellen lines, or approximately 10.63 letters. Two eyes were considered unchanged compared to longstanding measurements. Using LogMAR, the average improvement in vision for all eyes was 29.5%. The averagevisual acuity increasein eyes that improved was 33.3%. Findings were statistically significant with P<0.001.</p><p><strong>Conclusions: </strong>Using autologous BMSC per protocols developed in the SCOTS/SCOTS 2 clinical studies resulted in statistically significant visual acuity improvements in patients with DOA or Kjers Optic Neuropathy. Improvements occurred in 83.3% of eyes and averaged 29.5%. Mitochondrial transfer and neuroprotective exosome secretions from the BMSC may have been key to the improvements observed in this mitochondrial disease.</p>","PeriodicalId":21938,"journal":{"name":"Stem cell investigation","volume":" ","pages":"41"},"PeriodicalIF":0.0,"publicationDate":"2019-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/sci.2019.11.01","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37626894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of the CARE guideline as reporting standard in the <i>Stem Cell Investigation</i>.","authors":"","doi":"10.21037/sci.2019.11.02","DOIUrl":"https://doi.org/10.21037/sci.2019.11.02","url":null,"abstract":"","PeriodicalId":21938,"journal":{"name":"Stem cell investigation","volume":" ","pages":"40"},"PeriodicalIF":0.0,"publicationDate":"2019-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/sci.2019.11.02","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37626892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cord blood transplantation for bone marrow failure syndromes: state of art.","authors":"Simona Pagliuca,&nbsp;Annalisa Ruggeri,&nbsp;Régis Peffault de Latour","doi":"10.21037/sci.2019.10.04","DOIUrl":"https://doi.org/10.21037/sci.2019.10.04","url":null,"abstract":"<p><p>Hematopoietic stem cell transplantation (HSCT) and immunosuppressive therapy (IST) represent the milestones of the treatment algorithm for idiopathic and inherited bone marrow failure (BMF) disorders. However, patients lacking a suitable donor or failing IST still have a poor prognosis. Cord blood transplantation (CBT) has extended the possibility of HSCT for many patients in case of the absence of an eligible donor, and although in the last years, this procedure is less used in several hematological diseases, it remains an option for the treatment of patients with BMF syndromes. Nevertheless, optimization of conditioning regimen and cord blood unit selection is warranted to reduce the risk of graft failure and transplant-related mortality. This review summarizes the state of art of CBT in the field of BMF diseases, focusing on historical and recent issues in idiopathic aplastic anemia and inherited disorders.</p>","PeriodicalId":21938,"journal":{"name":"Stem cell investigation","volume":" ","pages":"39"},"PeriodicalIF":0.0,"publicationDate":"2019-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/sci.2019.10.04","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37626893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer stem cells and nanotechnological approaches for eradication.","authors":"Gholam Basati,&nbsp;Mojtaba Khaksarian,&nbsp;Saber Abbaszadeh,&nbsp;Hamed Esmaeil Lashgarian,&nbsp;Abdolrazagh Marzban","doi":"10.21037/sci.2019.10.07","DOIUrl":"https://doi.org/10.21037/sci.2019.10.07","url":null,"abstract":"<p><p>Cancer stem cells (CSCs) are currently known as the main cause of tumor recurrence. After chemotherapy is completed, CSCs proliferate and then differentiate to generate new tumor tissues. Similar to normal stem cells, this non-uniformly distributed cell population in the tumor tissue has self-renewal capacity and is responsible for survival of the tumor and difference in its genetic and metabolic characteristics. Followed by gene instability in CSCs, new phenotypic markers are aberrantly expressed in CSCs subpopulation. Hence, some of the surface markers and metabolic pathways that are upregulated in CSCs may be applied as specific targets for development of diagnostic and therapeutic approaches. In this review article, the distinctive properties of CSCs including signal pathways implicated in self-renewal and surface markers were discussed. Moreover, targeting CSCs based on their specific properties using nanodrugs was reviewed.</p>","PeriodicalId":21938,"journal":{"name":"Stem cell investigation","volume":" ","pages":"38"},"PeriodicalIF":0.0,"publicationDate":"2019-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/sci.2019.10.07","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37471386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence of acute promyelocytic leukemia across Europe: results of RARECAREnet-a population-based study.","authors":"Avinash G Dinmohamed,&nbsp;Otto Visser","doi":"10.21037/sci.2019.10.03","DOIUrl":"https://doi.org/10.21037/sci.2019.10.03","url":null,"abstract":"<p><p>The scarcity of studies performed over the past decades in Central and South America provided clues that the prevalence of acute promyelocytic leukemia (APL)-a rare and distinct subtype of acute myeloid leukemia-might be higher among descendants of Spaniards, as compared to other ethnic groups. Currently, a comprehensive apprehension on APL incidence across Europe has yet been established. Therefore, we conducted a population-based study to assess the incidence of APL across Europe. We selected all patients diagnosed with APL in Europe from the RARECAREnet database that holds data from 94 cancer registries across 27 European countries on rare malignancies diagnosed during 2000-2007. Age-standardized incidence rates (ASRs) with 95% confidence intervals (CIs) were calculated for the European pool per 100,000 person-years. Also, crude incidence rates with 95% CIs were calculated per 100,000 person-years by country. Overall, 1,876 patients with APL (48% male and 24% aged ≥65 years) were included in our analytic cohort. The overall ASR of APL was 0.112 (95% CI, 0.107-0.117) in Europe. The incidence of APL varied considerably across Europe, with the highest incidence in Spain (0.257; 95% CI, 0.205-0.317), as compared to the European average. Altogether, these finding adds additional support to the hypothesis that APL might be more prevalent among individuals with Spanish ancestry. Future research is warranted to specifically explore etiologic factors of APL across different genetic and environmental backgrounds.</p>","PeriodicalId":21938,"journal":{"name":"Stem cell investigation","volume":" ","pages":"37"},"PeriodicalIF":0.0,"publicationDate":"2019-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/sci.2019.10.03","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37471384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of selenium on freezing-thawing damage of mice spermatogonial stem cell: a model to preserve fertility in childhood cancers.","authors":"Mandana Beigi Boroujeni,&nbsp;Fatemeh Peidayesh,&nbsp;Afshin Pirnia,&nbsp;Nasim Beigi Boroujeni,&nbsp;Seyyed Amir Yasin Ahmadi,&nbsp;Mohammadreza Gholami","doi":"10.21037/sci.2019.10.01","DOIUrl":"https://doi.org/10.21037/sci.2019.10.01","url":null,"abstract":"<p><strong>Background: </strong>During treatment of childhood cancers, fertility of boys may be affected. Therefore, freezing spermatogonial stem cell (SSC) is recommended. However, freezing-thawing process may cause damage to SSCs. This study was conducted to evaluate protective effects of selenium on freezing-thawing damage of mice SSCs using investigation of cell viability and investigation of apoptosis related genes expression including <i>Fas</i>, <i>Caspase3</i>, <i>Bcl2</i>, <i>Bax</i> and <i>P53</i>.</p><p><strong>Methods: </strong>SSCs were extracted from 80 6-day-old mice. The SSCs were divided into four groups: cryopreservation along with selenium (low and high dose), vitrification along with selenium (low and high dose), cryopreservation control, and vitrification control. Trypan blue staining and real-time polymerase chain reaction (real-time PCR) were used to investigate cell viability and gene expression, respectively.</p><p><strong>Result: </strong>Comparison of cell viability in the experimental groups did not show a significant association. Expression of <i>Fas</i> and <i>Caspase3</i> was significantly lower in cryopreservation group with low-dose selenium. Expression of <i>Bcl2</i> was significantly lower in cryopreservation group with high-dose selenium. Expression of <i>Bax</i> and <i>Caspase3</i> was significantly lower in vitrification group with low-dose selenium, and expression of <i>P53</i> was significantly upper. Expression of <i>Bax</i> and <i>Fas</i> was significantly lower in vitrification group with high-dose selenium, and expression of <i>P53</i> was significantly upper (P<0.001).</p><p><strong>Conclusions: </strong>Selenium had dose dependent effect on apoptosis related genes profile. The only evident effect was the effect of low-dose selenium in cryopreservation on inhibition of apoptosis via extrinsic pathway.</p>","PeriodicalId":21938,"journal":{"name":"Stem cell investigation","volume":" ","pages":"36"},"PeriodicalIF":0.0,"publicationDate":"2019-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6917556/pdf/sci-06-2019.10.01.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37471383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lower T cell inhibitory receptor level in mononuclear cells from cord blood compared with peripheral blood.","authors":"Ying Lin, Jinrong Lin, Jingying Huang, Youchun Chen, Jiaxiong Tan, Yangqiu Li, Shaohua Chen","doi":"10.21037/sci.2019.09.01","DOIUrl":"https://doi.org/10.21037/sci.2019.09.01","url":null,"abstract":"T cell inhibitory receptors play important role in maintaining T cell homeostasis. The feature of such negative costimulator signal transduction pathway in cord blood (CB) T cells remains unclear. In this study, the expression levels of T cell inhibitory receptors including programmed death-1 (PD-1), cytotoxic T lymphocyte antigen-4 (CTLA-4), T cell immunoglobulin mucin-3 (Tim-3), lymphocyte activation gene-3 (LAG-3) and B and T lymphocyte attenuator (BTLA) were characterized in CB and compared with peripheral blood (PB). Significant lower expression of PD-1, CTLA-4, LAG-3 and BTLA was found in CB, while similar expression level of Tim-3 was showed between CB and PB. Together, different expression pattern of such T cell inhibitory receptor in CB is worthy to further discuss their role on immune response when CB is used in cord blood stem cell transplantation as well as allogeneic chimeric antigen receptor T-cell producing.","PeriodicalId":21938,"journal":{"name":"Stem cell investigation","volume":"6 1","pages":"35"},"PeriodicalIF":0.0,"publicationDate":"2019-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/sci.2019.09.01","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45367392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A revealing review of mesenchymal stem cells therapy, clinical perspectives and Modification strategies.","authors":"Pardis Saeedi, R. Halabian, A. I. Imani Fooladi","doi":"10.21037/sci.2019.08.11","DOIUrl":"https://doi.org/10.21037/sci.2019.08.11","url":null,"abstract":"Multipotent mesenchymal stem cells (MSCs) have been considerably inspected as effective tool for cell-based therapy of inflammatory, immune-mediated, and degenerative diseases, attributed to their immunomodulatory, immunosuppressive, and regenerative potentials. In the present review, we focus on recent research findings of the clinical applications and therapeutic potential of this cell type, MSCs' mechanisms of therapy, strategies to improve their therapeutic potentials such as manipulations and preconditioning, and potential/unexpected risks which should be considered as a prerequisite step before clinical use. The potential risks would probably include undesirable immune responses, tumor formation and the transmission of incidental agents. Then, we also review some of the milestones in the field, briefly discuss challenges and highlight the new guideline suggested for future directions and perspectives.","PeriodicalId":21938,"journal":{"name":"Stem cell investigation","volume":"6 1","pages":"34"},"PeriodicalIF":0.0,"publicationDate":"2019-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/sci.2019.08.11","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41381744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}